Serous effusions: Diagnosis of malignancy beyond cytomorphology. An analytic review

Postgraduate Medical Journal

Volumn 79, Issue 936, 2003, Pages 569-574

  Mohanty, S K ^a   Dey, P ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIGEN; CD44V ANTIGEN; GROWTH FACTOR; HERMES ANTIGEN; PROTEIN P53; TELOMERASE; TUMOR MARKER;

CELL PROLIFERATION; CELL STRUCTURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; EFFUSION; ELECTRON MICROSCOPY; ENZYME ACTIVITY; EVALUATION; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; IMAGE ANALYSIS; IMAGE CYTOMETRY; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY;

BLOOD GROUP ANTIGENS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GROWTH SUBSTANCES; HLA ANTIGENS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IN SITU HYBRIDIZATION; MICROSCOPY, ELECTRON; NUCLEOLUS ORGANIZER REGION; PLEURAL EFFUSION, MALIGNANT; POLYMERASE CHAIN REACTION; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0344844589     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.79.936.569     Document Type: Review

References (104)

1. Thunnissen FB, Peterse JL, van Pel R, et al. Reliability of fine needle aspiration cytology for distinguishing between carcinoma, lymphoma and sarcoma: the influence of clinical information. Cytopathology 1993;4:107-14.
2. Motherby H, Nadjari B, Friegel P, et al. Diagnostic accuracy of effusion cytology. Diagn Cytopathol 1999;20:350-7.
3. Hammar SP, Bockus DE, Remington FL, et al. Mucin-positive epithelial mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas. Ultrastruct Pathol 1996;20:293-325.
4. Roggli VL, Kolbeck J, Sanfilippo F, et al. Pathology of human mesothelioma: etiologic and diagnostic considerations. Pathol Annu 1987;22(pt 2):91-131.
5. Wang NS. Electron microscopy in the diagnosis of pleural mesotheliomas. Cancer 1973;31:1046-54.
6. Warhol MJ, Hickey WF, Corson JM. Malignant mesothelioma: intrastructural distinction from adenocarcinoma. Am J Surg Pathol 1982;6:307-14.
7. Esteban MJ, Yokota S, Husain S, et al. Immunocytochemical profile of benign and carcinomatous effusions: a practical approach to difficult diagnosis. Am J Clin Pathol 1990;94:698-705.
8. Cibas ES, Corson JM, Pinkus GS. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen. Hum Pathol 1987;18:67-74.
9. Mason MR, Bedrossian CW, Fahey CA. Value of immunocytochemistry in the study of malignant effusions. Diagn Cytopathol 1987;3:215-21.
10. Silverman JF, Nance K, Phillips B, et al. The use of immunoperoxidase panels for the cytologic diagnosis or malignancy in serous effusions. Diagn Cytopathol 1987;3:134-40.
11. Nance KV, Silverman JF. Immunocytochemical panel for the identification of malignant cells in serous effusions. Am J Clin Pathol 1991;95:867-74.
12. Skov BG, Stahel RA, Hirsch F. ME1-antibody labelling of primary bronchogenic tumors and extrapulmonary malignancies. Lung Cancer 1994;11:221-7.
13. Chang K, Pastan I, Willingham MC. Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. Int J Cancer 1992;51:548-54.
14. Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992;16:259-68.
15. Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer 1998;84:101-8.
16. Simsir A, Fetsch P, Mehta D, et al. E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthelss. Diagn Cytapathol 1999;20:125-30.
17. Delahaye M, Hoogsteden HC, Van der Kwast TH. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. J Pathol 1991;165:137-43.
18. Donna A, Betta PG, Bellingeri D, et al. Cytologic diagnosis of malignant mesothelioma in serous effusions using an antimesothelial-cell antibody (published correction appears in Diagn Cytopathol 1992;8:661). Diagn Cytopathol 1992;8:361-5.
19. Clark SP, Chou ST, Martin TJ, et al. Parathyroid hormone-related protein antigen localization distinguishes between mesothlioma and adenocarcinoma of the lung. J Pathol 1995;176:161-5.
20. Ko EC, Jhala NC, Shultz JJ, et al. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology. Am J Clin Pathol 2001;116:709-15.
21. Blobel GA, Moll R, Franke WW, et al. The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol 1985;121:235-47.
22. Ordonez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 1998;22:1215-21.
23. Ascoli V, Scalzo CC, Taccongna S, et al. The diagnostic value of thrombomodulin immunolocalization in serous effusions. Arch Pathol Lab Med 1995;119:1136-40.
24. Kennedy AD, King G, Kerr KM. HBME-1 and antithrombomodulin in the differential diagnosis of mesothelioma of pleura. J Clin Pathol 1997;50:859-62.
25. Kondi-Paphitis A, Addis BJ. Secretotry component in pulmonary adenocarcinoma and mesothelioma. Histopathology 1986;10:1279-87.
26. Doglioni C, Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-40.
27. Leers MP, Aarts MM, Theunissen PH. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998;32:209-16.
28. Bedrossian CWM, Bonsib S, Moran C. Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry. Semin Diagn Pathol 1992;9:124-40.
29. Ploten D, Menager M, Jeannesson P, et al. Improvement of the staining and visualization of the argyrophilic proteins of the nucleolar organizer region at optical level. Histochem J 1986;18:5-14.
30. Eskelinem MJ, Lipponen PC, Collan Y, et al. The role of nuclear organizer regions as prognostic factors in breast cancer. Eur J Cancer 1991;27:989-92.
31. Mourad WA, Erkman Balis B, Livingstone S, et al. Arygrophilic nucleolar organizer regions in breast carcinoma: correlation with DNA flow cytometry, histopathology and lymph node status. Cancer 1992;69:1739-44.
32. Sujathan K, Kannan S, Pillai KR, et al. Significance of AgNOR count in differentiating malignant cells from reactive mesothelial cells in serious effusions. Acta Cytol 1996;40:724-8.
33. Rocher AE, Blanco AM, Palaoro LA. Usefulness of AgNOR technique in the interpretation of serous effusions. Rev Med Chil 2000;128:963-8.
34. Pomjanski N, Motherby H, Buckstegge B, et al. Early diagnosis of mesothelioma in serous effusions using AgNOR analysis. Anal Quant Cytol Histol 2001;23:151-60.
35. Cibas ES. Application of flow cytometric DNA analysis to diagnostic cytology. Diagn Cytopathol 1995;13:166-71.
36. O'Leary TJ. Flow cytometry in diagnostic cytology. Diagn Cytopathol 1998;18:41-6.
37. Saha I, Dey P, Vohra H, et al. Role of DNA flow cytometry and image cytometry on effusion fluid. Diagn Cytopathol 2000;22:81-5.
38. Saikia UN, Dey P, Vohra H, et al. DNA flow cytometry of non-Hodgkin's Lymphomas: correlation with cytologic grade and clinical relapse. Diagn Cytopathol 2000;22:153-6.
39. Kumar UN, Dey P, Mondal AK, et al. DNA flow cytometry and bladder irrigation cytology in detection of bladder carcinoma. Diagn Cytopathol 2001;24:153-6.
40. Joensuu H, Klemi PJ, Eerola E. Diagnostic value of flow cytometric DNA determination combined with fine needle aspiration biopsy in thyroid tumors. Anal Quant Cytol Histol 1987;9:328-34.
41. Zabro RJ. Flow cytometric DNA analysis of effusions. Am J Clin Pathol 1991;95:2-4.
42. Joseph MG, Banerjee D, Harri P, et al. Multiparameter flow cytometric DNA analysis of effusions: a prospective study of 36 cases compared with routine cytology and immunohistochemistry. Mod Pathol 1995;8:686-93.
43. Evans D, Thornthwaite J, Ng ABP, et al. DNA flow cytometry of pleural effusions: comparison with pathology for the diagnosis of malignancy. Anal Quant Cytol Histol 1982;5:19-27.
44. Green LK, Griffin J. Increased natural killer cells in fluids. A new, sensitive means of detecting carcinoma. Acta Cytol 1996;40:1240-5.
45. Laurini JA, Garcia A, Elsner B, et al. Relation between natural killer cells and neoplastic cells in serous fluids. Diagn Cytopathol 2000;22:347-50.
46. Walb WA, Rainer RO, Memoli VA. Basic principles of image processing. Am J Clin Pathol 1992;98:493-501.
47. Schneller J, Eppich E, Greenebaum E, et al. Flow cytometry and Feulgen cytophotometry in evaluation of effusions. Cancer 1987;59:1307-13.
48. Maringer T, Gschwendtner A, Toetsch M, et al. Automated cell differentiation of bronchoalveolar lavage samples with two-step image analysis. Anal Quant Cytol Histol 1996;18:453-60.
49. Thunnissen FB, Buchholtz RT, Woutersen DP, et al. Clinical value of DNA image cytometry in effusions with atypia. Diagn Cytopathol 1999;21:112-16.
50. Saleh H, Bober P, Tabaczka P. Value of Ki67 immunostain in identification of malignancy in serous effusions. Diagn Cytopathol 1999;20:24-8.
51. Sahin AA, Ro JY, Brown RW, et al. Assessment of Ki67-derived tumor proliferate activity in colorectal adenocarcinoama. Mod Pathol 1994;7:17-22.
52. Esteban JM, Sheibani K. DNA ploidy analysis of pleural mesothelioma: its usefulness for their distinction from lung adenocarcinoma. Mod Pathol 1992;5:626-31.
53. Dalquen P, Baschiera B, Chaffard R, et al. MIB1 (Ki67) immunostaining of breast cancer cells in cytology smears. Acta Cytol 1997;41:229-32.
54. Sahn SA. The pleura. Am Rev Respir Dis 1988;138:184-234.
55. Serre G, Daste G, Vincent C, et al. Diagnostic approach to the patient with pleural effusions: cytologic analysis of pleural fluid. In: Deslauriers J, Lacquet UK, eds. International trends in general thoracic surgery. St Louis: Mosby, 1990;6:35-45.
56. Fenton KN, Richardson JD. Diagnosis and management of malignant pleural effusions. Am J Surg 1995;170:69-74.
57. Piantino P, Cellerino A. Tumor markers determination in extrahematic fluids. J Nucl Med Allied Sci 1990;34:128-36.
58. Ferroni P, Szpak C, Greiner JW, et al. CA72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers. Int J Cancer 1990;46:445-51.
59. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, et al. Diagnostic value of CA72-4, carcinoembryonic antigen, CA15-3 and CA19-9 assay in pleural fluid. A study of 207 patients. Cancer 1996;78:736-40.
60. Soletormos G, Nielsen D, Schioler V, et al. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Cnem 1996;42:564-75.
61. Spila A, Cavaliere F, Casaldi V, et al. CA72-4 serum marker -a new tool in the management of carcinoma patient. Cancer Invest 1995;13:227-38.
62. Grem J. The prognostic importance of tumor markers in adenocarcinoma of the gastrointestinal tract. Curr Opin Oncol 1997;9:380-7.
63. Pujol JL, Grenier J, Daures JP, et al. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993;53:61-6.
64. Plebani M, Basso D, Navagila P, et al. Clinical evaluation of seven tumor markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer 1995;72:170-3.
65. Doweck I, Barak M, Greenberg E, et al. Cyfra21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 1995;121:177-81.
66. Callet N, Cohen-Solal Le Nin CC, Berthelot E, et al. Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra21.1 determination. Eur J Gynecol Oncol 1998;19:50-6.
67. Morita T, Kikuchi T, Hashimoto S, et al. Cytokeratin-19 fragment (CYFRA21-1) in bladder cancer. Eur Urol 1997;32:327-44.
68. Salama G, Miedouge M, Rouzaud P, et al. Evaluation of pleural CYFRA21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions. Br J Cancer 1998;77:472-6.
69. Gallatin WM, Rosenman SJ, Ganji A, et al. Structure-function relationship of CD44 class of glycoproteins. Cell Mol Mech Inf 1991;2:131-50.
70. Picker LJ, Nakache M, Butcher EC. Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules in on diverse cell types. J Cell Biol 1989;109:927-37.
71. Culty M, Miyaka K, Kincade PW, et al. The hyaluronate receptor is a member of CD44 (H-CAM) family of cell surface glycoproteins. J Cell Biol 1990;111:2765-74.
72. Berner HS, Davidson B, Berner A, et al. Differential expression of CD44s and CD44v3-10 in adenocarcinoma cells in effusions. Virchows Arch 2000;436:330-5.
73. Kayser K, Markle C, Kugler C, et al. Integrated nuclear fluorescence and expression of hormone-binding sites in malignant pleural effusions. Anal Quant Cytol Histol 2000;22:364-74.
74. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;226:2011-15.
75. Hiyama E, Yokoyama T, Tatsumoto N, et al. Telomerase activity in gastric cancer. Cancer Res 1995;55:3258-62.
76. Hiyama K, Hiyama E, Ishioka S, et al. Telomerase activity in small cell and non-small cell lung cancer. J Natl Cancer Inst 1995;87:895-902.
77. Hiyama E, Gollahon L, Kotaoka T, et al. Teleomerase activity in human breast tumors. J Natl Cancer Inst 1996;88:116-22.
78. Sommerfeld H-J, Meeker AK, Piatyszek MA, et al. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996;56:218-22.
79. Anderson S, Shera K, Ihle J, et al. Telomerase activation in cervical cancer. Am J Pathol 1997;151:25-31.
80. Cunningham VJ, Markham N, Shroyer AL, et al. Detection of telomerase expression in fine-needle aspirations and fluids. Diagn Cytopathol 1998;18:431-6.
81. Mu XC, Brien TP, Ross JS, et al. Telomerase activity in benign and malignant cytologic fluids. Cancer 1999;25(87):93-9.
82. Toshima S, Arai T, Yasuda Y, et al. Cytological diagnosis and telomerase activity of cells in effusions of body cavities. Oncol Rep 1999;6:199-203.
83. Yang CT, Lee MH, Lan RS, et al. Telomerase activity in pleural effusions: diagnostic significance. J Clin Oncol 1998;16:567-73.
84. Dejmek A, Yahata N, Ohyashiki K, et al. In situ telomerase activity in pleural effusions: a promising marker for malignancy. Diagn Cytopathol 2001;24:11-15.
85. Eisenstein B. The polymerase chain reaction: a new method of using molecular genetics for medical diagnosis. N Eng J Med 1990;322:178-82.
86. Sakaguchi M, Virmani AK, Ashfaq R, et al. Development of a sensitive, specific reverse transcriptase polymerase chain reaction-based assay for epithelial tumor cells in effusions. Br J Cancer 1999;79:416-22.
87. Davidson B, Goldberg I, Berner A, et al. Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions. Am J Clin Pathol 2001;115:517-24.
88. Wolman SR. Fluorescence in situ hybridization: a new tool for the pathologist. Hum Pathol 1994;25:586-90.
89. Fiegl M, Kaufmann H, Zojer N, et al. Malignant cell detection by fluorescence in situ hybridization (FISH) in effusions from patients with carcinoma. Hum Pathol 2000;31:448-55.
90. Jia D, Zhang Z, Liu S, et al. Study on interphase cytogenetic abnormalities in malignant cells in pleural fluids from lung cancer cases. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2000;17:244-7.
91. Zebrowski BK, Yano S, Liu W, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999;5:3364-8.
92. Yanagawa H, Takeuchi E, Suzuki Y, et al. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother 1999;48:396-400.
93. Westermann AM, Harik E, Postma FR, et al. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 1998;9:437-42.
94. Zimmerman RL, Fogt F, Bibbo M. Diagnostic utility of sialosyl-Tn in discriminating carcinomatous cells from benign mesothelium in body cavity effusions. Acta Cytol 1999;43:1079-84.
95. Magyarosy E, Martin WJ, Chu EW, et al. Differential diagnostic significance of the paucity of HLA-I antigens on metastatic breast carcinoma cells in effusions. Pathol Oncol Res 1999;5:32-5.
96. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
97. Cote RJ, Jhanwar SC, Novick S, et al. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res 1991;51:5410-16.
98. Kafiri G, Thomas DM, Shepard NA, et al. P53 expression is common in malignant mesothelioma. Histopathology 1992;21:331-4.
99. Bennett WP, Borkowski A, Colby TV, et al. P53 mutation and immunopositivity in the pathogenesis of human bronchogenic carcinomas (abstract). Lab Invest 1993;68:129A.
100. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 protein in lung cancer correlates the class of p53 gene mutation. Oncogene 1992;7:743-9.
101. Rodrigues N, Rowan A, Smith MEF, et al. P53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990;87:7555-9.
102. Mullick SS, Green LK, Ramzy I, et al. P53 gene product in pleural effusions: practical use in distinguishing benign from malignant cells. Acta Cytol 1996;40:855-60.
103. Mayall F, Heryet A, Manga D, et al. p53 immunostaining is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology. Cytopathology 1997;8:9-12.
104. Zoppi JA, Pellicer EM, Sundblad AS. Diagnostic value of p53 protein in the study of serous effusions. Acta Cytol 1995;39:721-4.